Biomea Fusion Inc.
Clinical trials sponsored by Biomea Fusion Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New diabetes pill icovamenib enters Mid-Stage trial Results expected Mar 2027 (estimated)
- New diabetes pill shows promise for patients stuck on ozempic Results expected Jun 2027 (estimated)
-
Diabetes drug trial halted: could BMF-219 have boosted insulin?
Disease control CompletedThis study tested an experimental drug called BMF-219 in people with type 1 diabetes to see if it could help their bodies produce more insulin. The trial was stopped early, but researchers planned to compare insulin levels between those who got the drug and those who got a placeb…
Phase 2 • Sponsor: Biomea Fusion Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill shows promise in controlling blood sugar for type 2 diabetes
Disease control CompletedThis study tested a new daily pill, BMF-219, in healthy adults and people with type 2 diabetes. The goal was to see if it is safe and helps lower blood sugar levels over 26 weeks. About 443 participants took either the drug or a placebo to compare results.
Phase 1/2 • Sponsor: Biomea Fusion Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Healthy volunteers test new drug capsule with and without food
Knowledge-focused CompletedThis early-stage study looked at how taking a new drug called icovamenib with or without food changes the way the body absorbs it. Sixty healthy adults took the capsule in different conditions to measure drug levels in the blood. The goal was to gather information for future dosi…
Phase 1 • Sponsor: Biomea Fusion Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC